In all of these posts about the preliminary 14C, I'm surprised that almost nobody has commented on the actual contents of the document besides the fact that the A/S will be increased to 5 billion. If everyone would just read the entire document, most people's questions would be answered and their fears subside. Here's a quick breakdown:
The pre-14C gives 2 reasons for the need to increase the A/S:
So let's look at point (a). This is fully explained in detail within the pre-14C. As part of the agreement with Dr. Wei-Ping Min to in-license the Min IP, BMSN must make payments to Dr. Min upon certain milestones being reached:
1. Dr. Min will perform certain tasks for Regen as part of a consulting agreement. As compensation, Regen will pay Dr. Min $100k worth of common stock over a one year period in 12 equal payment. From the pre-14C:
2. Upon FDA approval of the Min IP IND, Regen will give Dr. Min 33,333 preferred shares which can be converted to $333k worth of common stock. The number of shares will be determined by the pps on that given day. From the pre-14C:
3. Upon development of the manufacturing procedure for the Min IP drug, Regen will give Dr. Min 33,333 preferred shares which can be converted to $333k worth of common stock. The number of shares will be determined by the pps on that given day. From the pre-14C:
4. Upon completion of a clinical trial protocol for Phase I and a Principal Investigator has been appointed, Regen will give Dr. Min 33,333 preferred shares which can be converted to $333k worth of common stock. The number of shares will be determined by the pps on that given day. From the pre-14C:
5. Upon successful completion of Phase I clinical trials, Regen will give Dr. Min $1 million worth of common shares. The number of shares will be determined by the pps on that given day. From the pre-14C:
So what does the above all mean? It means that BMSN will need plenty more common shares than what they have available in order to fully compensate Dr. Min. To illustrate the point, if you used today's pps ($0.0038), all of the compensation above would total over 552 MILLION common shares! The good thing about this is it is all performance based. If the Min IP does not get FDA approval, then BMSN is not on the hook for any of the above payouts. Obviously, as long shareholders, it is in our best interest that Dr. Min gets a boat load of shares, because that means the Min IP is well on it's way to potentially making Billions of dollars and lots of profits for shareholders. Also, as these milestones are completed, the pps will be a WHOLE LOT HIGHER than what it is today, therefore the number of shares required to compensate Dr. Min will be SIGNIFICANTLY LESS than the 552 million it would take at today's pps.
As far as point (b), my personal take is that they want the flexibility to be able to purchase/license more IP's like the Min IP, with common stock. This will require a significant amount of shares, as evidence above by the amount of shares required to pay Dr. Min for his IP.
Bottom line, this is not the horrible "end of the world" event that bashers are making it out to be. Just because they are increasing the A/S doesn't mean they will issue all of it or any where near all of the unissued shares. To give an example, another stock I am invested in, JAMN (aka Marley Coffee) has a little over 5.1 Billion A/S, yet their O/S is only slightly north of 90 Million. They've had over 5 Billion A/S for years, yet they've only increased their O/S slightly over that same time frame for some financing deals. Point is, O/S does not always eventually equal A/S.
Sorry for the length of the post, just hope to help other members understand better and not fall prey to fear mongering.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.